[A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].

Alfuzosin (dalphaz) has been tried in 32 patients with benign prostatic hyperplasia (BPH). The treatment lasted for 14 weeks: 2 weeks of placebo and 12 weeks of alfuzosin. The drug was given in a daily dose of 10 mg (5 mg twice a day). The response was registered in 87.5% of cases. Improvement of urination occurred by all the parameters of IPSS scale (the overall IPSS dropped by 10.5 scores). Dalphaz had a good hypotensive effect: high blood pressure lowered to normal, normal pressure did not change. Dalphaz was well tolerated in all the cases except one when an allergic eruption broke out.